Pharma Journalist -

SMi Reports: Interview excerpt with Bionical EMAS’ Executive VP, Tom Watson released for SMi’s 9th Annual Conference on Orphan Drugs & Rare Diseases, in London in less than 3 weeks…
Read More...

SMI Reports: Overview of networking opportunities and key features to expect from the upcoming HPAPI USA conference 2019, in Boston With is less than 4 weeks until the 2019 HPAPI USA…
Read More...

SMi Group Reports: CEO of twoXAR to present at SMi’s Ophthalmic Drugs conference commencing on 18th- 20th November 2019, in London The Ophthalmic Drugs conference is taking place on…
Read More...

Moderna, Inc., a clinical-stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients,…
Read More...

SpringWorks Therapeutics announced the European Commission has granted Orphan Drug Designation for nirogacestat, an oral, selective, small molecule, gamma-secretase inhibitor, for the…
Read More...

Blade Therapeutics, a biopharmaceutical company advancing novel anti-fibrotic therapies, announced the acquisition of ATXCo, Inc., including its core asset, PAT-409, a Phase I ready…
Read More...

Achillion Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for danicopan (ACH-4471) for treatment in combination…
Read More...

IMMUNOPRECISE ANTIBODIES, an industry leader in the discovery of novel, therapeutic antibodies, announces that Talem Therapeutics, its wholly-owned subsidiary, has entered into an LOI…
Read More...

Zealand Pharma A/S announces positive results in the pediatric Phase 3 trial with dasiglucagon for severe hypoglycemia in diabetes. Dasiglucagon is a potential first-in-class soluble…
Read More...

Aldeyra Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation to ADX-2191 for the prevention of proliferative vitreoretinopathy…
Read More...